Difference between revisions of "Dexrazoxane (Zinecard)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (25 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Intracellular chelating agent derived from EDTA. | + | Class/mechanism: Intracellular chelating agent derived from EDTA. Mechanism not fully understood, but hypothesized to protect against anthracycline-caused cardiomyopathy by interfering with iron-mediated free radical generation. Also used in cases of [[Vesicant & irritant chemotherapy|anthracycline extravasation]].<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=514 Dexrazoxane (Zinecard) package insert]</ref><ref>[[:File:Dexrazoxane.pdf | Dexrazoxane (Zinecard) package insert (locally hosted backup)]]</ref><ref>[http://www.pfizer.com/products/rx/rx_product_zinecard.jsp Zinecard manufacturer's website]</ref><ref>[http://totect.com/pdf/prescribing_information.pdf Dexrazoxane (Totect) package insert]</ref><ref>[http://totect.com/ Totect manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Efficacy references== | ||
| + | # Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, Knoblauch P, Rasmussen A, Dahlstrøm K, Jensen PB, Giaccone G. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007 Mar;18(3):546-50. Epub 2006 Dec 21. [https://pubmed.ncbi.nlm.nih.gov/17185744/ PubMed] | ||
| + | <!-- Results from this manuscript have been presented at the American Society of Clinical Oncology Scientific Sessions, Chicago, IL, June 1-5, 2012, and at the American Society of Pediatric Hematology/Oncology Annual Meeting, Cincinnati, OH May 15-17, 2008. --> | ||
| + | # '''POG 9404:''' Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: A report of the Children's Oncology Group randomized trial Pediatric Oncology Group 9404. J Clin Oncol. 2016 Mar 10;34(8):854-62. Epub 2015 Dec 23. [https://doi.org/10.1200/jco.2015.60.8851 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872007/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26700126/ PubMed] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://chemocare.com/druginfo/dexrazoxane.aspx Dexrazoxane (Zinecard) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/dexrazoxane.aspx Dexrazoxane (Zinecard) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/dexrazoxane-patient-drug-information Dexrazoxane (Zinecard) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dexrazoxane-patient-drug-information Dexrazoxane (Zinecard) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/dexrazoxane-patient-drug-information Dexrazoxane (Zinecard) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dexrazoxane-patient-drug-information Dexrazoxane (Zinecard) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code names:''' ADR-529, ICRF-187 | ||
| + | *'''Generic name:''' dexrazoxane hydrochloride | ||
| + | *'''Brand names:''' Cardioxane, Cyrdanax, Savene, Totect, Zinecard | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:Chemotherapy protective agents]] | ||
| + | [[Category:Chelators]] | ||
| + | |||
| + | [[Category:FDA approved in 1995]] | ||
Latest revision as of 01:04, 29 June 2024
General information
Class/mechanism: Intracellular chelating agent derived from EDTA. Mechanism not fully understood, but hypothesized to protect against anthracycline-caused cardiomyopathy by interfering with iron-mediated free radical generation. Also used in cases of anthracycline extravasation.[1][2][3][4][5]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Efficacy references
- Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, Knoblauch P, Rasmussen A, Dahlstrøm K, Jensen PB, Giaccone G. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007 Mar;18(3):546-50. Epub 2006 Dec 21. PubMed
- POG 9404: Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: A report of the Children's Oncology Group randomized trial Pediatric Oncology Group 9404. J Clin Oncol. 2016 Mar 10;34(8):854-62. Epub 2015 Dec 23. link to original article link to PMC article PubMed
Patient drug information
- Dexrazoxane (Zinecard) patient drug information (Chemocare)[6]
- Dexrazoxane (Zinecard) patient drug information (UpToDate)[7]
Also known as
- Code names: ADR-529, ICRF-187
- Generic name: dexrazoxane hydrochloride
- Brand names: Cardioxane, Cyrdanax, Savene, Totect, Zinecard
References
- ↑ 1.0 1.1 Dexrazoxane (Zinecard) package insert
- ↑ Dexrazoxane (Zinecard) package insert (locally hosted backup)
- ↑ Zinecard manufacturer's website
- ↑ Dexrazoxane (Totect) package insert
- ↑ Totect manufacturer's website
- ↑ Dexrazoxane (Zinecard) patient drug information (Chemocare)
- ↑ Dexrazoxane (Zinecard) patient drug information (UpToDate)